AAAAAA

   
Results: 1-4 |
Results: 4
Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21
Authors: Waite, DC Jacobson, EW Ennis, FA Edelman, R White, B Kammer, R Anderson, C Kensil, CR
Citation: Dc. Waite et al., Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21, VACCINE, 19(28-29), 2001, pp. 3957-3967
Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity
Authors: Boyaka, PN Marinaro, M Jackson, RJ van Ginkel, FW Cormet-Boyaka, E Kirk, KL Kensil, CR McGhee, JR
Citation: Pn. Boyaka et al., Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity, J IMMUNOL, 166(4), 2001, pp. 2283-2290
Plasmodium falciparum: Immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate
Authors: Gozar, MMG Muratova, O Keister, DB Kensil, CR Price, VL Kaslow, DC
Citation: Mmg. Gozar et al., Plasmodium falciparum: Immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate, EXP PARASIT, 97(2), 2001, pp. 61-69
QS-21 adjuvant
Authors: Kensil, CR
Citation: Cr. Kensil, QS-21 adjuvant, METH MOL M, 42, 2000, pp. 259-271
Risultati: 1-4 |